Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863436/36461/en/Voyager-Therapeutics-Announces-Selection-of-Development-Candidate-for-GBA1-Program-in-Collaboration-with-Neurocrine-Biosciences-Triggering-Milestone-Payment.html

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. The companies expect to file an Investigational New Drug (IND) application with the FDA for the program in 2025.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.